·
2 minute read
Navigating New FDA Guidance for Radiopharmaceuticals
Radiopharmaceuticals are emerging as one of the most promising frontiers in oncology, offering the ability to deliver targeted radiation directly to cancer cells while sparing healthy tissue. While the concept of using radiation in cancer therapy dates back almost a century with external beam radiotherapy, today’s systemically delivered radiopharmaceuticals represent an entirely new wave of innovation. With this promise comes new complexity, and the FDA recently released new draft guidance, Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development (2025), to raise the standards for how these therapies are developed and evaluated.
Michael Ritchie, Chief Commercial Officer at Champions Oncology, has seen this evolution firsthand. With over a decade at Champions leading commercial operations and contributing to R&D strategy, he recognizes both the opportunity and the challenges of this emerging space.
Raising the Bar: What the FDA Wants
The FDA’s new guidance makes clear that more is expected of sponsors developing radiopharmaceuticals. Beyond simply demonstrating efficacy, companies must now generate robust data on pharmacodynamics, therapeutic windows, and toxicity. Regulators want to see meaningful insights into dosimetry, acute toxicities, and long-term safety profiles. They are also encouraging developers to test different doses and schedules to better define the boundaries of both safety and effectiveness.
In short, the FDA is signaling that radiopharmaceuticals must be studied with the same rigor applied to other advanced oncology therapeutics, while also accounting for the unique properties of radioactive isotopes.
The Scientific Unknowns
Despite the excitement surrounding radiopharmaceuticals, there is still much we do not know. Unlike antibody-drug conjugates, where decades of research have built a strong understanding of organ tolerability and patient management, radiopharmaceuticals remain an open field. Key questions persist: Which tumor types respond best? What are the predictable toxicities? What makes for the most effective construct from a pharmaceutical sciences perspective? Answering these questions is essential if these therapies are to fulfill their clinical potential.
The Logistical Hurdles
Beyond the science, logistics present another layer of challenge. Radiopharmaceuticals operate in a highly regulated space tied to nuclear medicine. Isotopes are not always easy to source, and many clinical sites lack the infrastructure or certification to administer them. This constrains patient enrollment and trial execution. Compounding the issue, isotopes have a short half-life and shelf life. Unlike traditional drugs that can be stored for months, radiopharmaceuticals must be manufactured and administered almost immediately, requiring precise planning and coordination.
Charting the Path Forward
The future of radiopharmaceuticals is undeniably bright, but realizing their full potential will require navigating both scientific unknowns and logistical barriers. The FDA’s Oncology Therapeutic Radiopharmaceuticals guidance provides structure, but it also highlights the complexity of the journey ahead. Success will depend on deeper biological insights, smarter trial design, and operational excellence in manufacturing and delivery.
At Champions Oncology, we are committed to partnering with pharma and biotech innovators to address these challenges head-on. By leveraging our advanced preclinical models and translational platforms, we help generate the data and confidence needed to accelerate radiopharmaceutical development and bring these groundbreaking therapies closer to patients.
.jpg)
